N
NH TherAguix
Biotech & Life Sciences · Meylan, France · Founded 2015
NH TherAguix, a clinical stage company – First nanomedicine for cancer, combining imaging and radiotherapy MoreLess
NH TherAguix operates in the healthcare sector, specializing in nanomedicine to enhance the efficacy of radiotherapy treatments. The company primarily serves oncology patients and healthcare providers by developing gadolinium-based nanoparticles that improve the precision and effectiveness of radiotherapy. These nanoparticles interact with X-rays to intensify the damage to tumor tissues, thereby improving patient outcomes. NH TherAguix's business model revolves around research and development, clinical trials, and partnerships with medical institutions. Revenue is generated through licensing agreements, grants, and potential future sales of their proprietary treatments. The company aims to extend the lifespan and quality of life for cancer patients by making radiotherapy more effective and less harmful to healthy tissues. Keywords: nanomedicine, radiotherapy, oncology, gadolinium, nanoparticles, tumor targeting, healthcare, clinical trials, cancer treatment, medical innovation.
Company overview
NH TherAguix company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Meylan, France
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 55.4
Valuation & funding
NH TherAguix funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2019 | $15M | $59M | Supernova Invest · Bpifrance | — |
| SPINOUT✓Other financing | Jan 2015 | $0 | — | PULSALYS · French National Centre for Scientific Research - CNRS | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 5 |
| 2025 | 10 |
| 2024 | 22 |
| 2023 | 23 |
| 2022 | 20 |
Growth signals
NH TherAguix website traffic
Latest recorded traffic for NH TherAguix is 20K monthly website visits, up 7042.9% over the last three months. NH TherAguix's team declined 50% over the past year.
Comparisons
NH TherAguix compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
NH TherAguix's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where NH TherAguix has talent and traffic
team presence
In the news
Latest news about NH TherAguix
Recent press, funding announcements, and product moves mentioning NH TherAguix — open to read from the original sources.
Market sentiment
What the market is saying about NH TherAguix
An AI-synthesized read of the highest-engagement posts about NH TherAguix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NH TherAguix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.